ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation study of the revised ACR/EULAR remission criteria.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis.‘ (Abstract number: 1414) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What was the methodology of the validation study for these reformed criteria? (0:16)
- What were the findings of the study? (2:31)
- How would you consider applying these criteria? (6:03)
Disclosures: Paul Studenic has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
